Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Novo and Pfizer in Metsera takeover battle
In a surprising move, Novo Nordisk A/S has overbid Pfizer Inc.’s M&A tender for Metsera Inc by US$1.9bn.…
Roche breaks ground on US manufacturing facility
Roche’s Genentech unit has started work on a $700 million manufacturing facility in North Carolina, part of a…
Roche Petrelintide Data Recasts Obesity Opportunity And Pipeline Growth Story
Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…
Genentech petrelintide sheds 10.7% weight in Phase II
03/05/2026 – 01:45 PM – Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus…
Roche, Zealand shares fall on ‘undifferentiated’ obesity drug results
This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free…
Roche and Zealand’s obesity contender clears phase 2, but investors were looking for more
On paper, the study did what it was supposed to do. In the 493-patient ZUPREME-1 trial, petrelintide met…
Roche and Zealand’s Phase II obesity trial divides analyst opinion
Roche and Zealand Pharma’s co-developed amylin analogue, petrelintide, has met its primary endpoint in a Phase II trial,…
Roche, Zealand Pharma Obesity Drug Meets Clinical Trial’s Weight Loss Goals, But Can It Compete?
Obesity drug research is expanding to targets beyond GLP-1 with a goal of improving the side effect profile…
Roche, Zealand’s amylin weight loss drug fails to clear Lilly’s bar
Yet another potential weight loss competitor has fallen short of defending champion Eli Lilly’s rival candidate in the…
Roche announces positive Phase II results for petrelintide, an amylin analog developed for people living with overweight and obesity
F. Hoffmann-La Roche Ltd Petrelintide achieved up to 10.7% mean body weight reduction at week 42 versus 1.7%…
FDA pushes back decision on Sanofi’s BTK inhibitor; Roche makes a deal with Starpharma
Plus, news about Sciwind Biosciences, Ipsen, Genfit, Ascletis, AusperBio, Ensoma, Jasper Therapeutics, Verrica, Incyte and Johnson & Johnson:…